These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9617321)

  • 1. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
    Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
    Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59).
    Shibata J; Toko T; Saito H; Lykkesfeldt AE; Fujioka A; Sato K; Hashimoto A; Wierzba K; Yamada Y
    Cancer Chemother Pharmacol; 2000; 45(2):133-41. PubMed ID: 10663628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tamoxifen and the derivative (TAT) on cell cycle of MCF-7 in vitro.
    Tominaga T; Yoshida Y; Matsumoto A; Hayashi K; Kosaki G
    Anticancer Res; 1993; 13(3):661-5. PubMed ID: 8317894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
    Toko T; Shibata J; Nukatsuka M; Yamada Y
    Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
    ter Haar E; Day BW
    Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
    Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
    Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors.
    Toko T; Sugimoto Y; Matsuo K; Yamasaki R; Takeda S; Wierzba K; Asao T; Yamada Y
    Eur J Cancer; 1990 Mar; 26(3):397-404. PubMed ID: 2141500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antitumor activity of a new antiestrogenic drug, toremifene (NK622) against human breast cancer xenografts in nude mice].
    Kuroiwa S; Koyama M; Watanabe N; Ekimoto H; Ohnishi Y; Saito M; Maruo K; Inaba M; Tashiro T; Yamori T
    Gan To Kagaku Ryoho; 1993 Apr; 20(5):617-23. PubMed ID: 8470919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice.
    Zhang L; Kharbanda S; Chen D; Bullocks J; Miller DL; Ding IY; Hanfelt J; McLeskey SW; Kern FG
    Oncogene; 1997 Oct; 15(17):2093-108. PubMed ID: 9366526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
    Chen J; Power KA; Mann J; Cheng A; Thompson LU
    Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice.
    McLeskey SW; Kurebayashi J; Honig SF; Zwiebel J; Lippman ME; Dickson RB; Kern FG
    Cancer Res; 1993 May; 53(9):2168-77. PubMed ID: 8481920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
    Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
    Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
    Leclercq G; Devleeschouwer N; Heuson JC
    J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone independent murine carcinoma BX-1 spontaneously arising from nude mouse bearing Br-10, a hormone dependent human breast carcinoma strain].
    Kubota T; Oka S; Utsumi T; Enomoto K; Ishibiki K; Abe O; Koh J; Shiina E; Asanuma F; Yamada Y
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2081-6. PubMed ID: 3395136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)].
    Nomura Y; Nakajima M; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1045-63. PubMed ID: 9644320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.